SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxiss Investor Day and upcoming FDA reviews are drawing attention, with traders focused on launch preparations and the commercial potential of ulixacaltamide for essential tremor and relutrigine for rare epilepsies, alongside expected EMERALD data. Sentiment is largely bullish on the catalysts, while some caution that approvals, launch uptake, and relutrigines review timing remain uncertain.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application, citing insufficient evidence of benefit without a statistically significant overall-survival result despite strong progression-free-survival data. Traders are reacting to the setback and debating whether future HARMONi-3 results and the broader pipeline can sustain the long-term case.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas anticipated Phase 3 APPROACH topline results for HLP003 in major depressive disorder, a binary clinical catalyst that traders see as potentially pivotal for the companys psychedelic-therapy prospects. Bulls emphasize its adjunctive design and potential for shorter clinic sessions, while skeptics point to uncertainty about whether Phase 2 efficacy will hold up and raise concerns about dilution and governance.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Strong preliminary REGAIN results in recurrent glioblastoma are driving attention, with traders highlighting high response rates in a small evaluable group and survival among treated patients. The community is broadly bullish but notes that durability, safety, and results as enrollment expands still need validation, with managements review of the data a focal point.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile rebound are driving discussion, with traders debating whether liquidation-driven selling and concerns about ETF flows, the Binance hack and macro headwinds point to further downside or an oversold bounce. Bears warn of new lows, while bulls see support holding and argue the pullback may be nearing a bottom.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,699,860,951.91490568 with 589,238,106,731,035.4551592 in circulation. The last known price of Shiba Inu is 0.00000379 USD and is down -10.85 over the last 24 hours. It is currently trading on 1128 active market(s) with $78,538,817.41 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention amid weak, choppy price action and repeated bearish technical commentary, with traders questioning its fading momentum and long-term utility. Some holders are buying dips and anticipating a meme-coin rebound, while others expect further declines or are comparing it unfavorably with other tokens.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

The FAAs nationwide ground stop, attributed to an air-traffic-control communications outage, disrupted flights and pressured airline stocks including Delta. Traders debate whether the cancellations will materially hurt results or prove temporary; political and cyberattack explanations circulating in the community remain speculation, with no evidence cited to support them.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibbs quarterly results beat expectations and lifted its revenue outlook, while its adjusted earnings outlook was lowered because of licensing-related charges. Traders welcomed the sales performance but debated whether pipeline progress can offset patent-expiration pressures, with some also noting weak price momentum.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

Traders are focused on VXX as a hedge against a possible equity pullback and renewed volatility, with geopolitical and macro risks cited as concerns. The community is divided between expecting a volatility breakout and arguing that VXXs futures-rolling decay makes spikes likely to fade.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,218,624.4003947. The last known price of Ethereum is 1,739.90377069 USD and is down -9.84 over the last 24 hours. It is currently trading on 14359 active market(s) with $18,820,901,710.98 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp, broad crypto selloff, with traders pointing to risk-off sentiment, forced liquidations, and uncertainty around rates, ETF flows, and security concerns. Bearish posts warn of further downside, while others see oversold conditions and capitulation as a buying opportunity or potential setup for a bounce.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


kk55lat

kk55lat